Provided by Tiger Trade Technology Pte. Ltd.

Dyne Therapeutics, Inc.

26.10
+0.12000.46%
Post-market: 26.100.00000.00%19:30 EDT
Volume:1.18M
Turnover:31.06M
Market Cap:4.87B
PE:-7.79
High:26.87
Open:26.22
Low:26.02
Close:25.98
52wk High:27.31
52wk Low:11.92
Shares:186.58M
Float Shares:186.00M
Volume Ratio:0.71
T/O Rate:0.64%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.3486
EPS(LYR):-3.4740
ROE:-81.57%
ROA:-38.96%
PB:6.94
PE(LYR):-7.51

Loading ...

Dyne Therapeutics completes enrollment in ACHIEVE trial expansion cohort for z-basivarsen in DM1

Reuters
·
Jun 03

Dyne Therapeutics, - Registrational Expansion Cohort Enrolled 71 Participants; Topline Data Planned for Q1 2027

THOMSON REUTERS
·
Jun 03

Dyne Therapeutics, - Expects Potential U.S. Launch of Z-Basivarsen in H1 2028 Pending FDA Approval

THOMSON REUTERS
·
Jun 03

Dyne Therapeutics Announces Completion of Enrollment in Registrational Expansion Cohort of Achieve Trial of Z-Basivarsen for Myotonic Dystrophy Type 1 (Dm1)

THOMSON REUTERS
·
Jun 03

Dyne Therapeutics director Brian S. Posner acquires 2,000 common shares worth $36,420

Reuters
·
May 29

Analysts Offer Insights on Healthcare Companies: Dyne Therapeutics (DYN), Kura Oncology (KURA) and 3SBio (OtherTRSBF)

TIPRANKS
·
May 26

Dyne Therapeutics submits FDA BLA for Duchenne drug z-rostudirsen under priority review request

Reuters
·
May 26

Dyne Therapeutics, Inc - Submission Seeks Accelerated Approval Based on Dystrophin as Surrogate Endpoint

THOMSON REUTERS
·
May 26

Dyne Therapeutics, Inc - Requests Priority Review for Bla to Shorten FDA Review to 6 Months

THOMSON REUTERS
·
May 26

Dyne Therapeutics Announces Submission of Biologics License Application (Bla) to U.S. FDA for Z-Rostudirsen in Exon 51 Duchenne Muscular Dystrophy (Dmd)

THOMSON REUTERS
·
May 26

Top Dyne Therapeutics Insider Quietly Snaps Up More Shares in Bold Move

TIPRANKS
·
May 23

Dyne Therapeutics director Brian S. Posner acquires 2,500 shares worth $42,800

Reuters
·
May 23

Analysts Offer Insights on Healthcare Companies: Dyne Therapeutics (DYN) and Palvella Therapeutics (PVLA)

TIPRANKS
·
May 21

Dyne Therapeutics grants inducement awards to 17 hires, including 296,500 stock options

Reuters
·
May 21

Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
May 21

Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
May 21

Dyne initiates Phase 3 FORZETTO trial of z-rostudirsen in Duchenne muscular dystrophy

Reuters
·
May 20

Dyne Therapeutics Announces Initiation of Phase 3 Forzetto Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (Dmd) Ahead of Planned Bla Submission for U.S. Accelerated Approval

THOMSON REUTERS
·
May 20

Dyne Therapeutics (DYN) Gets a Buy from LifeSci Capital

TIPRANKS
·
May 16

Dyne Therapeutics Is Maintained at Outperform by Evercore ISI Group

Dow Jones
·
May 16